Chronic mucocutaneous candidiasis, from bench to bedside

European Journal of Dermatology

Volumn 20, Issue 3, 2010, Pages 260-265

  Eyerich, Kilian ^a   Eyerich, Stefanie ^a   Hiller, Julia ^a   Behrendt, Heidrun ^a   Traidl Hoffmann, Claudia ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

APECED; Candida; Chronic mucocutaneous candidiasis; IL 17; IL 22; T cell; Th17

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NYSTATIN; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

CANCER RISK; CANDIDA; CELLULAR IMMUNITY; DISEASE COURSE; ESOPHAGUS STRICTURE; HUMAN; INDIGESTION; MALABSORPTION; MUCOCUTANEOUS CANDIDIASIS; NEPHROTOXICITY; PATHOGENESIS; PROGNOSIS; RECOMMENDED DRUG DOSE; RECURRENT INFECTION; REVIEW; SIDE EFFECT; SKIN GRANULOMA; SQUAMOUS CELL CARCINOMA; TH1 CELL; TH17 CELL; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; CANDIDIASIS, CHRONIC MUCOCUTANEOUS; DISEASE PROGRESSION; HUMANS; IMMUNITY, CELLULAR; SKIN; TH1 CELLS;

EID: 77952802354     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.0910     Document Type: Review

References (66)

1. Kirkpatrick CH. Chronic mucocutaneous candidiasis. Pediatr Infect Dis J 2001; 20: 197-206.
2. Thorpe ES, Handley HE. Chronic tetany and chronic mycelial stomatitis in a child aged four and one-half years. AMA Am J Dis Child 1929; 38: 228-238
3. Craig JM, Schiff LH, Boone JE. Chronic moniliasis associated with Addison's disease. AMA Am J Dis Child 1955; 89: 669-684
4. Hung W, Migeon CJ, Parrot RH. A possible autoimmune basis for Addison's disease in three siblings, one with idiopathic hypoparathyroidism, pernicious anemia and superficial moniliasis. N Eng J Med 1963; 269: 658-663
5. Chilgren RA, Quie PG, Meuwissen HJ, Hong R. Chronic mucocutaneous candidiasis, deficiency of delayed hypersensitivity, and selective local antibody defect. Lancet 1967; 2: 688-693
6. Collins SM, Dominguez M, Ilmarinen T, et al. Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Br J Dermatol 2006; 154: 1088-1093 (Pubitemid 43727389)
7. Peterson P, Nagamine K, Scott H, et al. APECED: a monogenic autoimmune disease providing new clues to self-tolerance. Immunol Today 1998; 19: 384-386 (Pubitemid 28389698)
8. Shimaka N, Nusspaumer G, Holländer GA. Clearing the AIRE: on the pathophysiological basis of the autoimmune polyendocrinopathy syndrome type-1. Endocrinol Metab Clin North Am 2009; 38: 273-88 (vii.).
9. Von Schnurbein J, Lahr G, Posovszky C, Debatin KM, Wabitsch M. Novel homozygous AIRE mutation in a German patient with severe APECED. J Pediatr Endocrinol Metab 2008; 21: 1003-1009
10. Lawrence T, Puel A, Reichenbach J, et al. Autosomal-dominant primary immunodeficiencies. Curr Opin Hematol 2005; 12: 22-30.
11. Atkinson TP, Schaffer B, Grimbacher B, et al. An immune defect causing dominant mucocutaneous candidiasis and thyroid disease maps to chromosome 2p in a single family. Am J Hum Genet 2002; 69: 791-803. (Pubitemid 32868524)
12. Nahum A, Bates A, Sharfe N, Roifman CM. Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis. J Allergy Clin Immunol 2008; 12: 1220-1222
13. Klein RS, Harris CA, Small CR, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immune deficiency syndrome. N Eng J Med 1984; 311: 354-358
14. Zlogotora J, Shapiro MS. Polyglandular autoimmune syndrome type I among Jews. J Med Genet 1992; 29: 824-826
15. Rosatelli MC, Meloni A, Meloni A, et al. A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. Hum Genet 1998; 103: 428-434 (Pubitemid 28542953)
16. Ahonen P, Myllärniemi S, SipiläI, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Eng J Med 1990; 322: 1829-1836.
17. Björses P, Aaltonen J, Vikman A, et al. Genetic homogeneity of autoimmune polyglandular disease type I. Am J Hum Genet 1996; 59: 879-886
18. Wolff AS, Erichsen MM, Meager A, et al. Autoimmune polyendocrinopathy syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab 2007; 92: 595-603.
19. Eyerich K, Foerster S, Rombold S, et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol 2008; 128: 2640-2645
20. Ryan KR, Hong M, Arkwright PD, et al. Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutaneous candidiasis with or without APECED. Clin Exp Immunol 2008; 154: 406-414
21. Hong M, Ryan KR, Arkwright PD, et al. Clin Exp Immunol 2009; 156: 40-51.
22. Lilic D, Gravenor I. Immunology of chronic mucocutaneous candidiasis. J Clin Pathol 2001; 54: 81-83
23. Walker SM, Urbaniak SJ. A serum-dependent defect of neutrophil function in chronic mucocutaneous candidiasis. J Clin Pathol 1980; 33: 370-372
24. Yamazaki M, Yasui K, Kawai H, et al. A monocyte disorder in siblings with chronic candidiasis. A combined abnormality of monocyte mobility and phagocytosis-killing ability. Am J Dis Child 1984; 138: 192-196
25. Ashman RB, Papadimitriou JM. Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev 1995; 59: 646-672
26. Palma-Carlos AG, Palma-Carlos ML, da Silva SL. Natural killer (NK) cells in mucocutaneous candidiasis. Allerg Immunol (Paris) 2002; 34: 208-212
27. De Moraes-Vasconcelos D, Orii NM, Romano CC, et al. Characterization of the cellular immune function of patients with chronic mucocutaneous candidiasis. Clin Exp Immunol 2001; 123: 247-253
28. Eyerich K, Rombold S, Foerster S, Behrendt H, Hofmann H, Ring J, et al. Altered, but not diminished T cell response in chronic mucocutaneous candidiasis patients. Arch Derm Res 2007; 299: 475-481
29. Challacombe SJ. Immunologic aspects of oral candidiasis. Oral Surg Oral Med Oral Pathol 1994; 78: 202-210
30. Lilic D, Calvert JE, Cant AJ, et al. Chronic mucocutaneous candidiasis. II. Class and subclass of specific antibody responses in vivo and in vitro. Clin Exp Immunol 1996; 105: 213-219
31. Bentur L, Nesbet-Brown E, Levinson H, Roifman CM. Lung disease associated with IgG subclass deficiency in chronic mucocutaneous candidiasis. J Pediatr 1991; 118: 82-86
32. IUIS scientific group. Primary immunodeficiency diseases. Clin Exp Immunol 1999; 118 (suppl 1): 17.
33. De Moraes-Vasconcelos D, Orii NM, Romano CC, et al. Characterization of the cellular immune function of patients with chronic mucocutaneous candidiasis. Clin Exp Immunol 2001; 123: 247-253
34. Mencacci A, Perruccio K, Bacci A, Cenci E, Benedetti R, MartelliMF, et al. Defective antifungal t-helper 1 (TH1) immunity in a murine model of allogeneic T-cell-depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists. Blood 2001; 97: 1483-1490
35. Tavares D, Ferreira P, Arala-Chaves M. Increased resistance to systemic candidiasis in athymic or Interleukin-10-depleted mice. J Infect Dis 2000; 182: 266-273 (Pubitemid 30497813)
36. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of Interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004; 190: 624-631 (Pubitemid 38982105)
37. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007; 8: 639-646 (Pubitemid 46785128)
38. Conti HR, Shen F, Nayyar N, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 2009; 206: 299-311.
39. Lilic D, Gravenor I, Robson N, et al. Deregulated production of protective cytokines in response to Candida albicans infection in patients with chronic mucocutaneous candidiasis. Infect Immun 2003; 71: 5690-5699 (Pubitemid 37205622)
40. Lilic D, Cant AJ, Abinun M, et al. Chronic mucocutaneous candidiasis. I. Altered antigen-stimulated IL-2, IL-4, IL-6 and interferon-gamma (IFN-γ) production. Clin Exp Immunol 1996; 105: 205-212
41. Van der Graaf CAA, Netea MG, Drenth JPH, et al. Candidaspecific interferon-γ deficiency and Toll-like receptor polymorphisms in patients with chronic mucocutaneous candidiasis. Neth J Med 2003; 61: 365-369
42. Kobrynski LJ, Tanimune L, Kilpatrick L, et al. Production of T-helper cell subsets and cytokines by lymphocytes from patients with chronic mucocutaneous candidiasis. Clin Diagn Lab Immunol 1996; 3: 740-745 (Pubitemid 26388812)
43. Glocker EO, Hennigs A, Nabavi M, Schäffer AA, Woellner C, Salzer U, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009; 361: 1727-1735
44. Howell MD, Boguniewicz M, Pastore S, Novak N, Bieber T, Girolomoni G, et al. Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol 2006; 121: 332-338 (Pubitemid 44768007)
45. Albanesi C, Fairchild HR, Madonna S, et al. IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)- 1, and SOCS-3. J Immunol 2007; 179: 984-992
46. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-2279 (Pubitemid 44498362)
47. Eyerich K, Pennino D, Scarponi C, et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune respone. J Allery Clin Immunol 2009; 123: 59-66.e4.
48. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 1999; 1: 494-502.
49. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008: 1092-1102
50. Minegishi Y, Saito M, Nagasawa M, et al. Molecular explanation for the correlation between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med 2009; 206: 1291-1301
51. Lingelbach A, Seidl HP, Frimberger E, Traidl-Hoffmann C, Ring J, Hofmann H. Chronic mucocutaneous candidosis with severe esophageal stricture. Mycoses 2003; 46 (Suppl 1): 15-18
52. McGurk M, Holmes M. Chronic muco-cutaneous candidiasis and oral neoplasia. J Laryngol Otol 1988; 102: 643-645
53. Firth NA, O'Grady JF, Reade PC. Oral squamous cell carcinoma in a young person with candidosis endocrinopathy syndrome: a case report. Int J Oral Maxillofac Surg 1997; 26: 42-44
54. Rosa DD, Pasqualotto AC, Denning DW. Chronic mucocutaneous candidiasis and oesophageal cancer. Med Mycol 2008; 46: 85-91. (Pubitemid 351298246)
55. Malfertheiner P, Peitz U. The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia. Gut 2005; 54 (Suppl1): 13-20. (Pubitemid 40293004)
56. Eyerich K, Traidl-Hoffmann C, Albert A, et al. Lipomatous metaplasia after severe and chronic cutaneous inflammation. Dermatology 2008; 217: 52-55 (Pubitemid 351896569)
57. Valdimarsson H, Moss PD, Holt PJ, H Obbs JR. Treatment of chronic mucocutaneous candidiasis with leukocytes from HL-A compatible sibling. Lancet.
58. Levy RL, Bach ML, Huang S, et al. Thymic transplantation in a case of chronic mucocutaneous candidiasis. Lancet 1971; 2: 898-900.
59. Chapman SW, Sullivan DC, Cleary JD. In search of the holy grail of antifungal therapy. Trans Am Clin Climatol Assoc 2008; 119: 197-215.
60. Rautemaa R, et al. Activity of amphotericin b, anidulafungin, caspofungin, micafungin, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocoutaneous candidiasis. Diagn Mircrobial Infect Dis 2008; 62: 182-185
61. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimircob Agents Chemother 2006; 50: 2009-2015
62. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27: 369-388
63. McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005; 65: 2049-2068
64. Cross SA, Scott LJ. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections. Drugs 2008; 68: 2225-2255
65. Reboli AC, Rotstein D, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin study group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482
66. Moen MD, Lysen-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 2009; 69: 361-392